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We conclude that combining drugs with relatively low single-
agent activity, leads to improved results in these patients. This
effect has also been shown when oxaliplatin and irinotecan were
combined in fluorouracil-resistant colorectal carcinoma, as
compared to their single-agent activity (Scheithauer et al, 1999).
Our results are certainly comparable with those of Nomoto et al,
who also used irinotecan in combination with cisplatin in relapsed
disease; however, details regarding platinum sensitivity of their
patients were not given (Nomoto et al, 2002). These in vitro and in
vivo observations lead us to question whether single-agent phase II
studies, conducted in a highly refractory patient population may
best be able to identify potentially useful cytotoxics, and certainly a
negative result must be accepted with some degree of caution.
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Sir,
In their letter, Powles et al disagree with our conclusions drawn
from the results of a phase II study on single-agent irinotecan in
patients with refractory germ cell cancer (Kollmannsberger et al,
2002b). At the same time, they question whether single-agent
phase II studies may be the best way to identify new potentially
active drugs in these patients. This statement is based on
preclinical as well as on preliminary clinical data, which must,
however, be thoroughly discussed.
Preclinical studies demonstrating an increased level of expres-
sion of topoisomerase I in germ cell cancer specimens or an
impressive activity of SN 38, the active metabolite of irinotecan, in
cisplatin-resistant germ cell cancer cell lines, form a strong
rationale for the evaluation of irinotecan in refractory germ cell
cancer patients. However, since we know from many other agents
that an in vitro activity may not always translate into clinical
activity, these preclinical findings do not allow to draw the
conclusion that irinotecan is active in refractory germ cell cancer
patients. Evidence for clinical activity of new agents can only be
provided by prospective clinical trials. Single-agent studies are
typically employed to obtain hints of the potential activity of a new
agent and to form a rationale for potential combinations. Of
course, single-agent studies cannot detect a synergism with other
drugs. Combination regimens in patients with refractory germ cell
cancer may lead to improved results, but these combinations
should include active drugs. Our study investigating irinotecan in
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responded. Thus, the probability for a false rejection of an active
drug was less than 5% (study design according to Gehan, 1961),
which makes a clinical activity with 420% response rate of
irinotecan unlikely. We agree with Powles et al that the negative
results of a single phase II study should still be considered
carefully. However, our study investigating irinotecan single-agent
therapy in patients with refractory germ cell cancer was the second
study that tested a topoisomerase I inhibitor in these patients.
Topotecan, the second clinically available topoisomerase I
inhibitor, has also been ineffective in relapsed or refractory germ
cell cancer patients (Puc et al, 1995).
Based on the proven, but moderate activity of single-agents such
as paclitaxel, oral etoposide, oxaliplatin or gemcitabine with
response rates of 15–20% and median overall survival periods of
3–6 months in patients with refractory disease, the investigation of
combinations of active drugs is appropriate. Hinton et al (2001)
were the first who combined two drugs and demonstrated the
feasibility and efficacy of combination chemotherapy even in
heavily pretreated germ cell cancer patients. The rationale for the
combination of paclitaxel and gemcitabine, however, was based on
the activity of both drugs when given as single-agent therapy
(Motzer et al, 1994; Bokemeyer et al, 1996, 1999; Einhorn et al,
1999). In their letter, Powles et al report a very high response rate
of 67% and a median survival of 11þ months for the combination
of oxaliplatin, paclitaxel and irinotecan. These favourable results,
although still do not prove the activity of irinotecan in these
patients since the two other drugs, oxaliplatin and paclitaxel, have
been shown to be active in refractory germ cell cancer (Bokemeyer
et al, 1996; Kollmannsberger et al, 2002a). A high activity of
oxaliplatin/paclitaxel has already been demonstrated in cisplatin-
resistant patients with metastatic ovarian cancer indicating that
this combination may act synergistically and can overcome
cisplatin resistance (Faivre et al, 1999). Thus, although not yet
proven in a formal study, the combination of the two agents is very
likely to be also active in refractory patients. Thus, the results
reported by Powles may have been achieved solely with
oxaliplatin/paclitaxel and the potential additional benefit of
irinotecan cannot be derived from that study. In addition, patient
selection plays an important role. In the study by Miki et al
investigating the combination of irinotecan and cisplatin in
relapsed germ cell cancer patients, only four of 18 patients had
previously received high-dose chemotherapy plus blood stem cell
support and in three patients, cisplatin/irinotecan was used as
second-line therapy indicating that this may have been a rather
favourable patient group. Moreover, no details were given about
the cisplatin sensitivity of these patients (Miki et al, 2002).
Similarly in the ongoing study by Powles using a combination of
oxaliplatin, paclitaxel and irinotecan, only 22% of patients were
cisplatin-refractory and 22% had previously received high-dose
chemotherapy, which demonstrates still a more favourable risk
profile of these patients in contrast to our study. In all our
previous studies on refractory patients, the majority of these
patients had been pretreated with high-dose chemotherapy or were
truly cisplatin-refractory.
Thus, despite a strong rationale from in vitro results that
had led us to investigate the use of irinotecan in relapsed or
cisplatin-refractory germ cell cancer, no evidence for
a clinically meaningful activity of irinotecan has thus far
been provided. We clearly agree that patients with refractory
germ cell cancer need to be treated within prospective
clinical trails in order to learn more about possible therapeutic
strategies.
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